Swift decision-making to enable a smooth transition to a system of value-based pricing for drugs used by the NHS must now be taken, the Health Select Committee has concluded, following its inquiry into NICE.
Swift decision-making to enable a smooth transition to a system of value-based pricing for drugs used by the NHS must now be taken, the Health Select Committee has concluded, following its inquiry into NICE.
The committee was critical of the delay in setting out what a value-based pricing system for drugs entailed. Given that the government opened its consultation on the issue in December 2010, the committee said it was 'unacceptable' that the arrangements for value-based pricing had not been settled and that those who would have to work with those arrangements were still unclear about what the new drug-pricing regime would mean in practice.